Scott D. Gleason

1.1k total citations
29 papers, 722 citations indexed

About

Scott D. Gleason is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Psychiatry and Mental health. According to data from OpenAlex, Scott D. Gleason has authored 29 papers receiving a total of 722 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Cellular and Molecular Neuroscience, 19 papers in Molecular Biology and 4 papers in Psychiatry and Mental health. Recurrent topics in Scott D. Gleason's work include Neuroscience and Neuropharmacology Research (14 papers), Neurotransmitter Receptor Influence on Behavior (13 papers) and Receptor Mechanisms and Signaling (11 papers). Scott D. Gleason is often cited by papers focused on Neuroscience and Neuropharmacology Research (14 papers), Neurotransmitter Receptor Influence on Behavior (13 papers) and Receptor Mechanisms and Signaling (11 papers). Scott D. Gleason collaborates with scholars based in United States, United Kingdom and Austria. Scott D. Gleason's co-authors include Harlan E. Shannon, Jeffrey M. Witkin, J. David Leander, Xia Li, David L. Nelson, Virginia L. Lucaites, E. G. Schneider, H E Shannon, Mark J. Benvenga and Andrew Alt and has published in prestigious journals such as Pain, Journal of Pharmacology and Experimental Therapeutics and Biochemical Pharmacology.

In The Last Decade

Scott D. Gleason

29 papers receiving 706 citations

Peers

Countries citing papers authored by Scott D. Gleason

Since Specialization

Citations

This map shows the geographic impact of Scott D. Gleason's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott D. Gleason with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott D. Gleason more than expected).

Fields of papers citing papers by Scott D. Gleason

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott D. Gleason. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott D. Gleason. The network helps show where Scott D. Gleason may publish in the future.

Co-authorship network of co-authors of Scott D. Gleason

This figure shows the co-authorship network connecting the top 25 collaborators of Scott D. Gleason. A scholar is included among the top collaborators of Scott D. Gleason based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott D. Gleason. Scott D. Gleason is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A medium throughput rodent model of relapse from addiction with behavioral and pharmacological specificity 2019 ·Pharmacology Biochemistry and Behavior ·William J.A. Eiler, Scott D. Gleason, Jodi L. Smith, Jeffrey M. Witkin	2
2	An antidepressant-related pharmacological signature for positive allosteric modulators of α2/3-containing GABA A receptors 2018 ·Pharmacology Biochemistry and Behavior ·(unknown), (unknown), Rok Cerne, Scott D. Gleason, Jeffrey M. Schkeryantz, (unknown), Lalit K. Golani, (unknown), Michael M. Poe, Md Toufiqur Rahman, James M. Cook, James L. Fisher, Jeffrey M. Witkin	12
3	Effects of 5-HT7 receptor antagonists on behaviors of mice that detect drugs used in the treatment of anxiety, depression, or schizophrenia 2018 ·Behavioural Brain Research ·(unknown), Scott D. Gleason, Julie F. Falcone, Kjell Svensson, (unknown), Xia Li, Jeffrey M. Witkin	14
4	Evaluation of 5-HT7 receptor antagonism for the treatment of anxiety, depression, and schizophrenia through the use of receptor-deficient mice 2018 ·Behavioural Brain Research ·(unknown), Matthew A. Seager, Scott D. Gleason, Xia Li, Kurt Rasmussen, (unknown), George G. Nomikos, Aldemar Degroot, Jeffrey M. Witkin	23
5	Negative allosteric modulation of alpha 5-containing GABAA receptors engenders antidepressant-like effects and selectively prevents age-associated hyperactivity in tau-depositing mice 2018 ·Psychopharmacology ·(unknown), Margot Ernst, (unknown), Rok Cerne, Mark Wakulchik, Xia Li, Timothy M. Jones, Scott D. Gleason, (unknown), Jeffrey M. Schkeryantz, Md Toufiqur Rahman, Guanguan Li, Michael M. Poe, James M. Cook, Jeffrey M. Witkin	19
6	Further evaluation of the potential anxiolytic activity of imidazo[1,5- a ][1,4]diazepin agents selective for α2/3-containing GABA A receptors 2017 ·Pharmacology Biochemistry and Behavior ·Jeffrey M. Witkin, Rok Cerne, Mark Wakulchik, Joan Sallés, Scott D. Gleason, Timothy M. Jones, (unknown), Leggy A. Arnold, Jun‐Xu Li, (unknown), (unknown), James M. Cook, Michael M. Poe	17
7	Electroencephalographic, cognitive, and neurochemical effects of LY3130481 (CERC-611), a selective antagonist of TARP-γ8-associated AMPA receptors 2017 ·Neuropharmacology ·Jeffrey M. Witkin, (unknown), Gary Gilmour, Stephen N. Mitchell, (unknown), Scott D. Gleason, Wesley F. Seidel, Brian J. Eastwood, Andrew McCarthy, Warren J. Porter, Jon K. Reel, Kevin M. Gardinier, Akihiko Kato, Keith A. Wafford	12
8	Inquiries into the Biological Significance of Transmembrane AMPA Receptor Regulatory Protein (TARP) γ−8 Through Investigations of TARP γ−8 Null Mice§ 2015 ·CNS & Neurological Disorders - Drug Targets ·Scott D. Gleason, Akihiko Kato, Hai H. Bui, Linda Thompson, (unknown), Patrick V. Stutz, Ming‐Shang Kuo, Julie F. Falcone, Wesley H. Anderson, Xia Li, Jeffrey M. Witkin	11
9	Perampanel, an Antagonist of α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptors, for the Treatment of Epilepsy: Studies in Human Epileptic Brain and Nonepileptic Brain and in Rodent Models 2014 ·Journal of Pharmacology and Experimental Therapeutics ·Ruud Zwart, Emanuele Sher, Xingjie Ping, Xiaoming Jin, John R. Sims, (unknown), Scott D. Gleason, Patric J. Hahn, Kevin M. Gardinier, Douglas L. Gernert, Jon Hobbs, Jodi L. Smith, (unknown), Jeffrey M. Witkin	53
10	Further Evaluation of the Neuropharmacological Determinants of the Antidepressant-Like Effects of Curcumin 2013 ·CNS & Neurological Disorders - Drug Targets ·Jeffrey M. Witkin, (unknown), Linda Thompson, (unknown), Chunjin Ding, Beverly A. Heinz, John T. Catlow, Scott D. Gleason, Xia Li	14
11	mGlu2/3 Agonist-Induced Hyperthermia: An In Vivo Assay for Detection of mGlu2/3 Receptor Antagonism and its Relation to Antidepressant-Like Efficacy in Mice 2013 ·CNS & Neurological Disorders - Drug Targets ·Scott D. Gleason, (unknown), A. Ian Smith, (unknown), Wang Xs, B.A. Heinz, (unknown), M Baez, (unknown), David M. Bender, Jeffrey M. Witkin	23
12	In Vivo Occupancy of Dopamine D3 Receptors by Antagonists Produces Neurochemical and Behavioral Effects of Potential Relevance to Attention-Deficit–Hyperactivity Disorder 2012 ·Journal of Pharmacology and Experimental Therapeutics ·(unknown), Anne B. Need, Eleni T. Tzavara, Bruno Giros, C. Overshiner, Scott D. Gleason, Mark Wade, Anna‐Karin Johansson, Kenneth W. Perry, George G. Nomikos, Jeffrey M. Witkin	26
13	Multiple dopamine receptors mediate the discriminative stimulus effects of dihydrexidine in rats 2011 ·Behavioural Pharmacology ·Scott D. Gleason, Tinggui Yin, Sheila P. Little, Neil W. DeLapp, Jeffrey M. Witkin	1
14	Anxiolytic-like effects through a GLUK5 kainate receptor mechanism 2007 ·Neuropharmacology ·Andrew Alt, (unknown), Paul L. Ornstein, Scott D. Gleason, David Bleakman, Robert E. Stratford, Jeffrey M. Witkin	19
15	A parametric analysis of punishment frequency as a determinant of the response to chlordiazepoxide in the Vogel conflict test in rats 2007 ·Pharmacology Biochemistry and Behavior ·Scott D. Gleason, Jeffrey M. Witkin	6
16	In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders 2006 ·Psychopharmacology ·Andrew Alt, (unknown), Ann Marie L. Ogden, Xia Li, Scott D. Gleason, David O. Calligaro, David Bleakman, Jeffrey M. Witkin	27
17	Effects of dopamine D1 receptor full agonists in rats trained to discriminate SKF 38393 2004 ·Behavioural Pharmacology ·Scott D. Gleason, Jeffrey M. Witkin	4
18	Influence of light cycle on response to 5-HT1A ligands in punished responding in rats 1999 ·Behavioural Pharmacology ·Scott D. Gleason, J. David Leander	2
19	Meta-chlorophenylpiperazine induced changes in locomotor activity are mediated by 5-HT1 as well as 5-HT2C receptors in mice 1998 ·European Journal of Pharmacology ·Scott D. Gleason, Harlan E. Shannon	30
20	Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice 1997 ·Psychopharmacology ·Scott D. Gleason, Harlan E. Shannon	202

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact